Abstract
ObjectivesSerum gamma-glutamyltransferase (γ-GT) predicts incident cardiovascular disease and mortality. The present study examined whether γ-GT also is associated with prognosis in patients with stable coronary heart disease. Methods and resultsThis study included 1152 participants (aged 30–70 years at baseline) of an in-patient rehabilitation programme after acute coronary syndrome, recruited in two rehabilitation clinics in Germany in the years 1999–2000 (KAROLA study). Until year 8 follow-up, 147 participants had experienced a non-fatal or fatal secondary cardiovascular disease event. Confounder-adjusted Cox proportional hazards models revealed an increase in risk for secondary events over ascending γ-GT quartiles, with hazard ratios (95% confidence interval) of 1.21 (0.72–2.03), 1.32 (0.80–2.16) and 1.75 (1.08–2.83) for the 2nd, 3rd and 4th in reference to the lowest quartile (Ptrend=0.024). The association with all-cause mortality examined as a secondary outcome was slightly stronger (hazard ratio of 4th quartile: 1.97 [1.15–3.36]; Ptrend=0.017). ConclusionsIn patients with stable coronary heart disease, serum γ-GT was associated with prognosis independent of a variety of established risk markers. The association appeared similar to that reported for primary cardiovascular disease, which should motivate additional studies of its clinical utility in cardiovascular patient care.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
